Filing Flows › Harrow (HROW) › Recalls, complaints & regulation
Harrow (HROW): recalls and clinical trials
Harrow (HROW) beyond its filings: 1 recall in the last 12 months (1 in five years, 0 Class I); 2 active clinical trials.
Latest recalls
- 2026-04-29 · FDA drug · FRESHKOTE LUBRICANT EYEDROPS, Sterile, 0.33 FL OZ (10mL), Harrow Eye LLC, Nashville, TN USA.
Harrow's latest quarter
Harrow, Q2 2026: revenue $70.7M (+11% year over year), operating margin -15.6%, net loss $17.3M, operating cash flow −$9.8M. The chart follows the revenue to costs, profit and cash.
Questions
Has Harrow had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 1 in the last 12 months.
How many clinical trials does Harrow have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.